RedHill Biopharma

EBGLYSS Receives Positive CHMP Opinion for Moderate-to-Severe Atopic Dermatitis Almirall S.A. announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the marketing authorization of EBGLYSS (lebrikizumab) for the treatment o...

Horizon Dishes Out Million Dollars to get Arrowhead's RNAi Drug Arrowhead Pharmaceuticals and Horizon Therapeutics have announced a research and development collaboration to advance the treatment landscape for uncontrolled gout. Under the terms and conditions, Arrowhead is bound to receive an upfront sum of U...

The Nontuberculous mycobacterial infection market worth is expected to grow at a CAGR of 6.6% by 2030 owing to robust NTM infection pipeline, rising prevalence among immunocompromised as well as immunocompetent populations, and a considerable shift towards branded therapeutics options. Planet Earth hosts a dive...

Slowly or rapidly growing bacteria- Nontuberculous mycobacteria (NTM), might appear innocuous, however, NTM infections have a notably higher total prevalence of 3,65,273 in the 7MM, estimates DelveInsight. Despite the global prevalence, clear from the facts and figures, the available therapies are entirely on an in...

Nontuberculous mycobacteria (NTM) are members of the Mycobacterium genus other than Mycobacterium tuberculosis complex and Mycobacterium leprae. NTM is a significant cause of chronic lung disease in immunosuppressed individuals and people suffering from chronic lung diseases such as chronic obstructive pulmonary di...

If dementia genes are found, drug discovery can be accelerated in brain disorders The overproduction of a protein called tau has been detected in the neuron degeneration that causes Alzheimer’s and other forms of dementia. But the exact genetic process that causes tau is still a mystery. Scientists of the University...